Home > Insider Trading > Filing (0001209191-21-070986)

Filing Details

Accession Number:: 0001209191-21-070986
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-12-22 18:42:10
Reporting Period:: 2021-12-20

Accepted Time:: 2021-12-22 18:42:10
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1370053	Anaptysbio Inc	ANAB	Pharmaceutical Preparations (2834)	203828755

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1654495	Hamza Suria	C/O Anaptysbio, Inc. 10770 Wateridge Circle, Suite 210 San Diego CA 92121	President, Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-12-20	36,645	$1.12	105,245	No	4	M	Direct
Common Stock	Disposition	2021-12-20	11,915	$34.89	93,330	No	4	S	Direct
Common Stock	Disposition	2021-12-20	19,208	$35.75	74,122	No	4	S	Direct
Common Stock	Disposition	2021-12-20	5,522	$36.40	68,600	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2021-12-20	36,645	$0.00	36,645	$1.12

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2022-01-31	No	4	M	Direct

Footnotes

The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.25 to $35.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.26 to $36.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.26 to $36.52, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
The stock option grant was issued on February 1, 2012, is fully vested and exercisable until its expiration date of January 31, 2022.
In addition to the remaining options to purchase 0 shares of common stock as set forth in Table II above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 1,118,893 shares of common stock, which options vest according to their terms, and (ii) 68,600 shares of common stock held directly.